Bill Clinton Prauds Results of CBD Clinical Trials
Recently, former U.S. President Bill Clinton publicly expressed his support for the therapeutic use of CBD, praising the results of a private trial investigating the substance as a potential alternative to opioid painkillers. After reviewing project documentation provided to the Clinton Foundation—one of the key sponsors of the project—Clinton called the results from companies Orcosa and TR Processing (TRP) “extremely promising.”
“For many years, our Foundation has been searching for effective alternatives to opioid pharmaceutical drugs, which, according to all available data, are the main cause of harmful opioid addiction among many of our fellow citizens,” a press release on behalf of Mr. Clinton stated. “The trials conducted at New York University, with the participation of private companies, show that CBD is a safe and accessible substitute for such medications.”
Details of the Clinical Trial
The trial involved 99 volunteers aged 17 to 75, who received a CBD extract as a replacement for standard medical painkillers during their post-surgical recovery. The results showed that, on average, the ORAVEXX-branded CBD extract was significantly more effective at relieving pain and both physical and psychological discomfort than a placebo pill. Importantly, the substance did not exhibit the typical side effects associated with opioid painkillers, confirming the findings of dozens of similar private trials and thousands of personal testimonials from cannabis users.
Media Response and Controversy
The activist organization Marijuana Moment attempted to contact Mr. Clinton for a personal comment on the trial results, but was only able to reach his press office, which declined to speak with the media. Interestingly, the press release from the president appeared on the Foundation’s website for a day before being mysteriously removed, only to be quickly restored later. This has led to speculation that, despite Clinton’s previous comments supporting cannabis reform, his staff may have been reluctant to associate his name too closely with this particular project.
While the activist community generally welcomed Clinton’s statement, some members voiced criticism regarding certain organizers of the project. They pointed out that Andrea Barthwell, a founder of one of the companies involved, previously headed the national drug policy office and had often spoken out against the medical use of cannabis, at one point calling it “a legally sanctioned way to circumvent criminalization policies.” In her defense, it should be noted that she held this position some time ago, before she had access to more reliable data on the properties of cannabis and its active components.